Second Primary Cancers in Patients With Castration Resistant Prostate Cancer

Prostatic Neoplasms Clinical Trial

— BOCARP  

Official title:

Second Primary Cancers in Patients With Castration Resistant Prostate Cancer (BOCARP)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02702908
• Other study ID #: 18044
• Secondary ID: EUPAS12665
• Status: Completed
• Phase: N/A
• First received: March 4, 2016
• Last updated: January 18, 2018
• Start date: March 15, 2016
• Est. completion date: October 20, 2017

Study information

• Verified date: January 2018
• Source: Bayer
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This study aims at estimating the incidence of second primary malignancies as well as the overall survival among metastasized prostate cancer (mPC) and metastasized castrate-resistant prostate cancer (mCRPC) patients not treated with radium-223-dichloride.

Description:

This study aims at estimating the incidence of second primary malignancies as well as the overall survival among mPC and mCRPC patients not treated with radium-223-dichloride. The source of data for this study will be the German Pharmacoepidemiological Research Database (GePaRD). A retrospective cohort study covering the time period from 2004 to 2013 will be conducted. The study population will comprise CRPC patients developing bone metastases. These patients will be followed up for the occurrence of second primary malignancies, end of study, or death due to any cause. As this study serves as a historical control group for a single-arm observational study, incidence rates of second primary malignancies obtained from these studies will be compared by the standardized incidence ratio using results from this study as a reference.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 6442
• Est. completion date: October 20, 2017
• Est. primary completion date: October 20, 2017
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Members of the mPC cohort will have to fulfill all of the following criteria:

• Valid information on sex, age and the region of residence

• A period of at least 12 months of continuous insurance preceding cohort entry

• Diagnosis of PC (ICD-10 Code C61) in the study period (01-Jan-2004 to 31-Dec-2011)

• Diagnosis of bone metastases (ICD-10 Code C79.5) in the enrolment period (01-Jan-2005 to 31-Dec-2011)

• In addition to the criteria of the mPC cohort, members of the mCRPC will additionally have to fulfill:

• One of the following in the enrolment period and before or at the same time with bone metastases

• Discontinuation of the initial chemical castration, change of the agent or modality of the Androgen deprivation therapy (ADT), or start of treatment for advanced Prostate cancer (PC) after the primary ADT.

• Surgical castration and initiation of ADT treatment

• Treatment with medication specific to mCRPC.

Exclusion Criteria:

• Patients will be excluded from the mPC and from the mCRPC populations if they meet one of the following criteria:

• First PC diagnosis later than 2 months after the diagnosis of bone metastases, or

• Use of any radiopharmaceuticals for bone metastases (e.g., samarium, strontium, rhenium, radium)

Related Conditions & MeSH terms

• Neoplasms, Second Primary
• Prostatic Neoplasms

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Bayer

Country where clinical trial is conducted

Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidences of Second primary malignancies are characterized by the following ICD-10 codes: C00-C76, C81-C96, D00-D09, D37-D48.		Up to 10 years
Secondary	Overall survival		Up to 10 years

External Links

•   Click here and search for drug information provided by the FDA.
•   Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.